AbbVie, Regenxbio to develop, commercialize RGX-314 for retinal diseases
Click Here to Manage Email Alerts
AbbVie and Regenxbio have entered into a partnership to develop and commercialize RGX-314, an investigational gene therapy, for the treatment of retinal diseases, according to a press release.
Regenxbio will be responsible for completing ongoing trials, and the companies will collaborate on future trials, including a second pivotal trial investigating the treatment for wet age-related macular degeneration.
AbbVie will make an upfront payment of $370 million to Regenxbio, which may be eligible to receive up to $1.38 billion in development, regulatory and commercial milestones, the release said. The companies will share equally in the net profits of RGX-314 sales in the United States. Outside of the U.S., AbbVie will pay Regenxbio tiered royalties on net sales of the therapy.
“AbbVie is a strong, complementary partner for Regenxbio. We expect to leverage AbbVie’s global developmental and commercial infrastructure within eye care with our expertise in AAV gene therapy clinical development and deep in-house knowledge of manufacturing and production to continue the development of RGX-314,” Kenneth T. Mills, president and CEO of Regenxbio, said in the release.
Regenxbio will lead manufacturing for clinical development and U.S. commercial supply, and AbbVie will lead manufacturing for commercial supply outside of the U.S.
The deal is expected to close by the end of the year.
Read more about
Click Here to Manage Email Alerts